another quick one before i go to work.
EMD
chart looks like its setting up nicely , if it can break 27 there is no overhead resistance.
A bit if an overview on the company.
Emyria advances multiple drug registration programs; establishes pure cannabinoid delivery platform; secures exclusive rights to major MDMA-analogue library; clinical advisory strengthened
Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed clinical drug
development and care delivery company, is pleased to report on the Company's activities for the quarter ending September 30, 2021.
Highlights:
Launched development of a unique TGA- and FDA-compliant cannabinoid dose form with major US contract research organisation, Altasciences
Obtained exclusive access to a library of more than 100 novel MDMA analogues developed at the University of Western Australia (UWA); potential to develop multiple treatments targeting major psychiatric and neurological disorders; pre-clinical data of one MDMA analogue class shows potential in reducing symptoms associated with Parkinson's disease treatment
Boosted drug development and clinical advisory with addition of renowned neuropharmacologist, Dr. Mat Martin-Iverson and Consultant Psychiatrist and Pain Medicine Fellow-in-training, Dr. Jeremy Tannenbaum
Emyria well funded to accelerate drug development programs with $4.5M cash as of 30 Sep 2021, and a further $1.1M R&D tax incentive expected in Q2, FY21/22
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: 25 Oct
another quick one before i go to work.EMD chart looks like its...
-
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)